Findlay Park Partners LLP Cuts Holdings in Becton, Dickinson and Company $BDX

Findlay Park Partners LLP trimmed its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.3% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 951,200 shares of the medical instruments supplier's stock after selling 32,300 shares during the period. Becton, Dickinson and Company comprises 1.9% of Findlay Park Partners LLP's investment portfolio, making the stock its 27th biggest position. Findlay Park Partners LLP owned approximately 0.35% of Becton, Dickinson and Company worth $143,945,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock worth $1,827,000 after buying an additional 1,354 shares during the last quarter. United Bank grew its position in Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock valued at $887,000 after buying an additional 993 shares during the period. Marshall Wace LLP increased its holdings in Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier's stock worth $5,491,000 after buying an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC raised its position in Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier's stock worth $4,048,000 after acquiring an additional 6,058 shares during the period. Institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 11,779 shares of company stock worth $1,974,669. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Price Performance

BDX opened at $191.95 on Friday. The firm has a 50-day moving average price of $161.58 and a 200-day moving average price of $161.13. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $192.30. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $52.89 billion, a price-to-earnings ratio of 57.82, a PEG ratio of 13.53 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the prior year, the company posted $3.68 EPS. Becton, Dickinson and Company's revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is 126.51%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BDX. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research note on Thursday, August 13th. The Goldman Sachs Group lowered their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a report on Wednesday, May 27th. Citigroup reiterated a "buy" rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. TD Cowen increased their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a report on Wednesday, August 5th. Finally, Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of "Hold" and an average price target of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source